JMS-053
a potent and selective PTP4A tyrosine phosphatase inhibitor
Also Known As:
7-imino-2-phenylthieno(3,2-c)pyridine-4,6(5H,7H)-dione
Networked: 7
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Lazo, John S:
6 articles
(01/2021 - 02/2018)
|
| 2. | Sharlow, Elizabeth R:
6 articles
(01/2021 - 02/2018)
|
| 3. | Wipf, Peter:
6 articles
(01/2021 - 02/2018)
|
| 4. | Rastelli, Ettore J:
4 articles
(01/2021 - 12/2019)
|
| 5. | Hart, Duncan J:
3 articles
(01/2021 - 12/2019)
|
| 6. | Tasker, Nikhil R:
3 articles
(01/2021 - 12/2019)
|
| 7. | Blanco, Isabella K:
3 articles
(12/2020 - 10/2018)
|
| 8. | McQueeney, Kelley E:
3 articles
(12/2020 - 02/2018)
|
| 9. | Cornelison, Robert:
2 articles
(01/2021 - 02/2018)
|
| 10. | Landen, Charles N:
2 articles
(01/2021 - 02/2018)
|
Related Diseases
| 1. | Ovarian Neoplasms (Ovarian Cancer)
01/01/2023
- " JMS-053 caused a concentration- and time-dependent decrease in the activated form of STAT3, Y705 phospho-STAT3, in ovarian cancer cells treated in vitro. " 02/02/2018
- " Importantly, JMS-053 displayed anticancer activity in a murine xenograft model of drug resistant human ovarian cancer. " 02/02/2018
- " In human ovarian cancer cells, JMS-053 impeded migration, disrupted spheroid growth, and decreased RhoA activity. " 12/01/2020
- " In the presence of serum albumin, the potency of JMS-053 as an in vitro inhibitor of PTP4A3 and human A2780 ovarian cancer cell growth was reduced. " 01/01/2023
- " We generated A2780 and OVCAR4 ovarian cancer cells resistant to JMS-053, and the resulting cells were not crossresistant to paclitaxel, cisplatin, or teniposide. "
|
| 2. | Neoplasms (Cancer)
|
|
Related Drugs and Biologics
Related Therapies and Procedures